CEREBROVASCULAR DISEASE

VINPOCETINE

1. Doses of vinpocetine (10 mg 3 times/day for 30 days then 5 mg 3 times/day for 60 days) improved chronic cerebral dysfunction in elderly patients without side effects.

J. AM. GERIATR. SOC. (USA), 1987, 35/5 (425‑430)
A double‑blind placebo controlled evaluation of the safety and efficacy of vinpocetine in the treatment of patients with chronic vascular senile cerebral dysfunction
Balestreri R.; Fontana L.; Astengo F.

2. Doses of vinpocetine (10 mg 3 times/day for 30 days then 5 mg 3 times/day for 60 days) significantly improved symptoms in 87 %elderly patients with central nervous system degenerative disorders without side effects.

CURR. THER. RES., CLIN. EXP. (USA), 1986, 40/4 (702‑709)
A double‑blind clinical trial of vinpocetine in the treatment of cerebral insufficiency of vascular and degenerative origin
Manconi E.; Binaghi F.; Pitzus F.

3. One intravenous dose of vinpocetine (10 mg) and oral vinpocetine (5 mg 3 times/day for 1 month) improved cerebral circulation, blood flow in the brain, and memory without side effects.

ARZNEIMITTEL‑FORSCH. (GERMANY, WEST), 1976, 26/10A (1947‑1950)
Rheoencephalographic and psychological studies with ethyl apovincaminate in cerebral vascular insufficiency
Hadjiev D.; Yancheva S.

4. Doses of vinpocetine (10 mg as infusion) reduced cerebral vascular resistance, and increased cerebral fraction of cardiac output, increased cerebral blood flow and decreased total vascular resistance in patients with cerebrovascular disease.

ARZNEIMITTEL‑FORSCH. (GERMANY, WEST), 1976, 26/10A (1945‑1947)
Effect of ethyl apovincaminate on the cerebral circulation; studies in patients with obliterative cerebral arterial disease
Solti F.; Iskum M.; Czako E.